Carelabs케어랩스

Carelabs is loss-making at the operating line and is pursuing a merger that would absorb Babytalk, while its shares have fallen about 52% over the past year.

Carelabs runs mobile healthcare and beauty platforms, including Goodoc and Babytalk, plus marketing and solutions businesses. Over the last twelve months to H1 2026 it reported revenue of ₩74.0B and an operating loss of ₩6.3B, but net income of ₩17.9B, a gap the data does not explain. At ₩2,000 per share, the market value is about ₩38.8B.

What stands out

• Revenue has been roughly flat to down for several years, from ₩93.9B in 2021 to ₩81.7B in 2025 and ₩74.0B on a trailing basis.
• Operating income has been negative in most recent years, with a 2025 operating loss of ₩2.9B, and the trailing free cash flow is about -₩21.6B.
• Reported net income is positive on a trailing basis (₩17.9B) despite the operating loss, so the profit figure depends on items outside operations that the data does not detail.
• The company holds about ₩20.2B in cash and reports no borrowings, with liabilities at 35.7% of equity.
• Filings and a news report show a merger decision to absorb Babytalk, with a shareholders' meeting called and an amended merger attachment filed in October 2026.
• Foreign ownership fell from 3.6% to 2.4% over about 60 days, and 20-day foreign flows were net selling.

What to watch

• Shareholders' meeting date, merger terms and any share-exchange details for the Babytalk merger, which the data does not specify.
• Whether operating losses and negative free cash flow narrow in upcoming results; the next periodic report is not yet in the data.
• The executive and major-shareholder trading plan filed on 26 October 2026, which may signal future share sales.